Payment overview · 2025
General Payments
$320.46
24 reported records · 5 companies
Healthcare provider profile · identity verified
Terry Matthew James, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ADDISON, AL · NPI 1225250640
Verified facts
What the public records show
CMS Open Payments records show Terry Matthew James, M.D. received $320.46 in general payments during 2025 across 24 reported records.
GlaxoSmithKline, LLC. accounted for 57.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $183.11 | 57.1% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.33 | 16.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.72 | 11.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.95 | 10.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.35 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.46 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $177.44 | 16 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $5.67 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $5.67 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 750 | 118 |
| Gabapentin | Gabapentin | 500 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 135 |
| Losartan Potassium | Losartan Potassium | 375 | 131 |
| Alprazolam | Alprazolam | 356 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 95 |
| Tramadol Hcl | Tramadol Hcl | 302 | 55 |
| Furosemide | Furosemide | 279 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 78 |
| Omeprazole | Omeprazole | 260 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 79 |
| Lisinopril | Lisinopril | 250 | 72 |
| Cefdinir | Cefdinir | 240 | 183 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 239 | 74 |
| Metformin Hcl | Metformin Hcl | 222 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 81 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 219 | 66 |
| Montelukast Sodium | Montelukast Sodium | 218 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 69 |
| Meloxicam | Meloxicam | 211 | 71 |
| Clonazepam | Clonazepam | 209 | 27 |
| Pregabalin | Pregabalin | 208 | 27 |
| Lorazepam | Lorazepam | 207 | 29 |
| Eliquis | Apixaban | 200 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 63 |
| Prednisone | Prednisone | 183 | 118 |
| Tizanidine Hcl | Tizanidine Hcl | 181 | 51 |
| Simvastatin | Simvastatin | 170 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 49 |
| Potassium Chloride | Potassium Chloride | 155 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 54 |
| Carvedilol | Carvedilol | 138 | 46 |
| Jardiance | Empagliflozin | 138 | 28 |
| Trazodone Hcl | Trazodone Hcl | 136 | 42 |
| Ozempic | Semaglutide | 133 | 26 |
| Metformin Hcl Er | Metformin Hcl | 132 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 36 |
| Tresiba Flextouch U-200 | Insulin Degludec | 108 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 106 | 17 |
| Mounjaro | Tirzepatide | 105 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 25 |
| Allopurinol | Allopurinol | 94 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 73 |
| Celecoxib | Celecoxib | 89 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 24 |
| Famotidine | Famotidine | 86 | 33 |
| Sertraline Hcl | Sertraline Hcl | 85 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 25 |
| Farxiga | Dapagliflozin Propanediol | 82 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 77 | 11 |
| Azithromycin | Azithromycin | 75 | 63 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 18 |
| Januvia | Sitagliptin Phosphate | 75 | 14 |
| Ondansetron Odt | Ondansetron | 74 | 30 |
| Estradiol | Estradiol | 73 | 22 |
| Glimepiride | Glimepiride | 72 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 19 |
| Diazepam | Diazepam | 65 | 11 |
| Atenolol | Atenolol | 62 | 17 |
| Meclizine Hcl | Meclizine Hcl | 62 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 45 |
| Clonidine Hcl | Clonidine Hcl | 58 | 16 |
| Alendronate Sodium | Alendronate Sodium | 57 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Methocarbamol | Methocarbamol | 56 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Mupirocin | Mupirocin | 53 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Fluconazole | Fluconazole | 49 | 33 |
| Ibuprofen | Ibuprofen | 49 | 12 |
| Xarelto | Rivaroxaban | 49 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Sucralfate | Sucralfate | 45 | suppressed |
| Finasteride | Finasteride | 43 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Nystatin | Nystatin | 39 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 26 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Donepezil Hcl | Donepezil Hcl | 36 | 13 |
| Spironolactone | Spironolactone | 36 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 13 |
| Amoxicillin | Amoxicillin | 34 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Valsartan | Valsartan | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Humalog | Insulin Lispro | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320.46 · 24 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, FARXIGA, JARDIANCE, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error